Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683160 | 0.84 | GSK3B (0.56) | CDK4GSK3BLMNAGSK3ACCND1 | |
| SCHEMBL17210881 | 0.83 | CCR6 (0.53) | LMNAHTTMEN1CYP1A2MAPT | |
| SCHEMBL15797143 | 0.82 | GSK3B (0.46) | CDK4GSK3BLMNAGSK3ACCND1 | |
| SCHEMBL17210883 | 0.82 | EIF2AK2 (0.43) | CDK4LMNACCND1CDK2HTT | |
| SCHEMBL17210892 | 0.77 | DDX3X (0.48) | LMNAHTTMEN1MAPTMAPK1 | |
| SCHEMBL17211123 | 0.77 | CCR6 (0.47) | LMNAHTTMEN1CYP1A2MAPT | |
| SCHEMBL17210888 | 0.75 | CCR6 (0.48) | LMNAHTTMEN1CYP1A2MAPT | |
| SCHEMBL17210889 | 0.75 | CCR6 (0.43) | GSK3BLMNAHTTMEN1MAPT | |
| SCHEMBL17210897 | 0.74 | MAPT (0.45) | CA1CA2CA4CA6CDK4 | |
| SCHEMBL17210887 | 0.74 | MAPT (0.43) | GSK3BMEN1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993463-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9724331-B2 | Use of maleimide derivatives for preventing and treating leukemia | CENTOGENE AG (DE) | 2017-08-08 | — | — | US | disclosed |
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE AG (DE) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | MGMT, CBR3, IDH3A | CA1 206/4885CA2 266/4885CA4 177/4885 |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | MCL1, NPM1, FLI1 | CA1 243/4885CA2 550/4885CA4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.